Alzheimer’s is a highly debilitating disease that affects certain areas of the brain. Here is the new drug that changes everything.
Alzheimer’s is a form of dementia that affects many people and causes loss of memory as well as other intellectual abilities. In particular, the symptoms that affect patients with this pathology are memory loss, difficulty completing tasks and states of confusion.
In this regard, however, it may be useful to know that a new drug has been discovered that would be able to prevent and counteract the protein that would be responsible for the disease.
Alzheimer’s, the new drug that changes everything
46 patients with an average age of 66 participated in the study in question. These were injected with a drug BIIB080, specifically 3 doses of the same. Its function would be to prevent the RNA from producing a protein indicated as responsible for the onset of the disease in question.
In a second step, the results obtained were compared with those obtained by another group of people who were given a placebo. What is shitty is that the medicine did not cause any side effects. In a nutshell, the first tests of this new drug show us that it affects the tau protein.
The accumulation of the latter, in fact, for many experts and according to what various studies have revealed, would be the cause of the disease Alzheimer. In any case, it is important to underline that there are other scholars who argue that the accumulation of the aforementioned protein would simply be a consequence of the disease itself and not the cause.
However, those mentioned are tests that are just beginning. Therefore, the real efficacy and safety of the drug still need to be demonstrated with further investigations. It is however true that it is the first drug able to intervene on the tau protein. Indeed, with reference to the drugs approved up to now – namely aducanumab and lecanemab – they tend to intervene on the accumulation of amyloid plaques.
This is the first time that a gene therapy capable of reducing tau protein levels has been developed. As it is clear, although the study has provided some interesting data, it must be emphasized how the number of subjects tested was too low to ensure large-scale results.
In this regard, the experts who conducted the study in question said that these are really important results. They are the demonstration that the drug is able to slow down the disease by blocking the cause that triggers it.